Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer 1

Similar documents
Positron emission tomography (PET and PET/CT) in recurrent colorectal cancer 1

Ultrasound-guided highintensity

IQWiG Reports - Commission No. A Ezetimibe for hypercholesterolaemia 1. Executive Summary

Stents for the treatment of intracranial arterial stenosis: VISSIT study and acute treatment in Germany 1

Executive Summary. Evaluation of the therapeutic benefits and harms of exenatide 1. IQWiG Reports - Commission No. A05-23

IQWiG Reports Commission No. A05-05C. Executive Summary

Executive Summary. IQWiG Reports Commission No. V06-02C

Executive Summary. Positron emission tomography (PET and PET/CT) in malignant lymphoma 1. IQWiG Reports Commission No. D06-01A

Idelalisib Benefit assessment according to 35a Social Code Book V 1

Safinamide (Addendum to Commission A15-18) 1

Biotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1

Perampanel Benefit assessment according to 35a Social Code Book V 1

Executive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1

Involvement of people affected

Ramucirumab (colorectal cancer)

Nivolumab Addendum to Commission A

Sofosbuvir/velpatasvir (chronic hepatitis C)

Biomarker-based tests to support the decision for or against adjuvant systemic chemotherapy in primary breast cancer

IQWiG Reports - Commission No. A05-19B. Executive Summary

Saxagliptin/metformin Benefit assessment according to 35a Social Code Book V 1

Guselkumab (plaque psoriasis)

Osimertinib (lung cancer)

Early benefit assessment of new drugs 5-year experiences of AMNOG (from IQWiG s point of view)

Sitagliptin/metformin Benefit assessment according to 35a Social Code Book V 1

Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1

Executive Summary. Non-drug local procedures for treatment of benign prostatic hyperplasia 1. IQWiG Reports - Commission No.

Ibrutinib (chronic lymphocytic leukaemia)

Aclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1

Vedolizumab Benefit assessment according to 35a Social Code Book V 1

IQWiG Reports Commission No. A Ceritinib

Addendum to Commission A12-02 Rilpivirine/emtricitabine/ tenofovir 1

Addendum to Commission A14-12 (canagliflozin) 1

Ceritinib (non-small cell lung cancer)

IQWiG Reports Commission No. A Dulaglutide

Summary HTA. Arthroplasty register for Germany. HTA-Report Summary. Gorenoi V, Schönermark MP, Hagen A

Ixekizumab (plaque psoriasis)

IQWiG Reports Commission No. A Regorafenib

Empagliflozin/metformin

IQWiG Reports Commission No. A Edoxaban

Lurasidone Benefit assessment according to 35a Social Code Book V 1

Osimertinib (non-small cell lung cancer)

Mepolizumab (asthma)

Osteodensitometry in primary and secondary osteoporosis

Ceritinib (non-small cell lung cancer)

Eribulin (liposarcoma)

Recommendations on Screening for Colorectal Cancer 2016

Do minimum volume regulations for health care interventions improve the quality of care? A systematic review

Sacubitril/valsartan

General Methods a. Version 4.0 of

Positive Results on Fecal Blood Tests

Lisdexamfetamine dimesylate Benefit assessment according to 35a Social Code Book V 1

Rapid Report A13-07 Version 1.0 Treatment of Hemophilia Patients May 28, 2015

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests

Submission of comments on 'Policy 0070 on publication and access to clinical-trial data'

School of Dentistry. What is a systematic review?

Pharmaceutical Benefits and the Economic Crisis in European Countries: The case of Germany

Ramucirumab (colorectal cancer)

PROSPERO International prospective register of systematic reviews

Ibrutinib (chronic lymphocytic leukaemia)

Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A

Ref: E 007. PGEU Response. Consultation on measures for improving the recognition of medical prescriptions issued in another Member State

Dupilumab (atopic dermatitis)

EPF s response to the European Commission s public consultation on the "Summary of Clinical Trial Results for Laypersons"

Systematic reviews vs. rapid reviews: What s the difference?

GATE CAT Intervention RCT/Cohort Studies

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist.

Meta-analyses: analyses:

Outcomes assessed in the review

The MASCC Guidelines Policy

Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto

Standards for the reporting of new Cochrane Intervention Reviews

Challenges and Opportunities with Rapidly-Changing Biomedical Technologies:

EBM Journal Club: Does Ginkgo Biloba improve memory in elder group

El equilibrio entre regulación-innovación en la fijación de precios y financiación de medicamentos OR The AMNOG Law

Secukinumab (plaque psoriasis)

Summary HTA. Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease

Title: A note on the graphical presentation of prediction intervals in random effects meta-analysis

Conflict of interest in randomised controlled surgical trials: Systematic review, qualitative and quantitative analysis

KEY ISSUES FOR LITERATURE SEARCHING

DATE: 17 July 2012 CONTEXT AND POLICY ISSUES

Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

Elbasvir/grazoprevir (chronic hepatitis C)

Screening Mammography for Women Aged 40 to 49 Years at Average Risk for Breast Cancer

City of Encinitas Housing Division Limited English Proficiency (LEP) Plan

Database of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.

Advice Statement. Advice Statement November Advice for NHSScotland. Why is SHTG looking at this topic?

Diagnostic tests for autism spectrum disorder(asd) in preschool children(review)

Greetings to all of you who provide valuable and vital health, human and related services in our communities!

Colour vision screening: a critical appraisal of the literature New Zealand Health Technology Assessment

Prevention approaches

GATE CAT Diagnostic Test Accuracy Studies

Summary HTA. HTA-Report Summary

International concepts related to prehospital emergency treatment in terminally ill patients a prospective questionnaire-based study

Author's response to reviews

Cancer Prevention and Control, Client-Oriented Screening Interventions: Reducing Client Out-of-Pocket Costs Colorectal Cancer (2008 Archived Review)

Definitions of substandard and falsified medical products

Cancer Prevention and Control, Client-Oriented Screening Interventions: Reducing Client Out-of-Pocket Costs Breast Cancer (2008 Archived Review)

Setting The setting was primary and secondary care. The economic study was carried out in Taiwan.

d) Patients with moderately to severely active Crohn s disease who have had an inadequate response with, lost

Transcription:

IQWiG Reports Commission No. S11-01 Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer 1 Executive Summary 1 Translation of the executive summary of the final report Bewertung des Nutzens einer Früherkennungsuntersuchung für Personen unter 55 Jahren mit familiärem Darmkrebsrisiko (Version 1.0; Status: 29 May 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.

Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer Contracting agency: Federal Joint Committee Commission awarded on: 21 March 2011 Internal Commission No.: S11-01 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 35685-0 Fax: +49 (0)221 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Institute for Quality and Efficiency in Health Care (IQWiG) - i -

This report was prepared in collaboration with external experts. IQWiG is solely responsible for the content of the report. According to 139b (3) No. 2 of Social Code Book (SGB) V, Statutory Health Insurance, external experts who are involved in the Institute s research commissions must disclose all connections to interest groups and contract organizations, particularly in the pharmaceutical and medical devices industries, including details on the type and amount of any remuneration received. The Institute received the completed form Disclosure of conflicts of interest from each external expert. The information provided was reviewed by a Committee of the Institute specifically established to assess conflicts of interests. The information on conflicts of interest provided by the external experts is presented in Appendix I of the full report. No conflicts of interest were detected that could endanger professional independence with regard to the work on the present commission. External experts: Viktoria Gloy Jos Kleijnen Frank Kolligs Kate Misso David Weller Robert Wolff IQWiG thanks the external experts for their collaboration in the project. IQWiG employees: 2 Julia Kreis Naomi Fujita (until 27 July 2012) Elke Hausner Annegret Herrmann-Frank (until 15 January 2012) Klaus Koch Stefan Sauerland Anke Schulz Guido Skipka 2 Due to legal data protection regulations, employees have the right not to be named. Institute for Quality and Efficiency in Health Care (IQWiG) - ii -

Executive summary In its letter of 21 March 2011 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the patient-relevant benefit of screening for colorectal cancer in people under 55 years of age with a family history of colorectal cancer (with the exception of hereditary forms of the disease). Research question The research question of the report was divided into several sub-goals: Sub-goal A: Determination of the risk of disease in people with a positive family history Within the framework of sub-goal A the risk of developing colorectal cancer or dying from the disease was determined in people with a positive family history. Sub-goal B: Assessment of the diagnostic accuracy of family history tools Within the framework of sub-goal B it was examined how reliable (i.e. with what diagnostic accuracy) family history tools that could be used during screening can identify people with a higher risk due to a positive family history within the normal population. Sub-goal C: Comparative benefit assessment of comprehensive screening strategies using family history tools Within the framework of sub-goal C the question was to be answered as to what benefit a screening strategy offers in which a family history tool was initially to be applied in the normal population under 55 years of age to identify patients at higher risk due to a positive family history. People with a positive test result were subsequently to be offered to participate in a screening procedure. In this context it was also of interest whether different screening strategies (e.g. use of different family history tools) differed in their benefit. Sub-goal D: Comparative benefit assessment of different screening procedures within a screening strategy in persons with an increased risk due to a positive family history. If no studies were found for sub-goal C, it was to be examined what benefit different measures within the framework of modified screening had for people in whom an increased risk due to a positive family history had already been determined. This related to different screening procedures (especially colonoscopy and faecal occult-blood testing, FOBT) but also to other potential differences in the screening strategies (e.g. different time intervals between the tests). Methods For the various sub-goals the assessment was conducted on the basis of different study designs. Cohort studies, embedded case-control studies and case-control studies were used for sub-goal A. Studies providing data on diagnostic accuracy were used for sub-goal B. Institute for Quality and Efficiency in Health Care (IQWiG) - 1 -

Randomized intervention studies (randomized controlled trials, RCTs) as well as clearly prospective, but non-randomized intervention studies with concurrent control groups (controlled clinical trials, CCTs) were used for the sub-goals C and D. For this purpose a systematic literature search was conducted in the following databases: MEDLINE, EMBASE, the NHS Economic Evaluation Database (Economic Evaluations) and the Cochrane Central Register of Controlled Trials (Clinical Trials). In addition, a search for relevant systematic reviews was conducted in the databases MEDLINE and EMBASE parallel to the search for relevant primary studies, as well as by means of a search in the Cochrane Database of Systematic Reviews (Cochrane Reviews), the Database of Abstracts of Reviews of Effects (Other Reviews), and the Health Technology Assessment Database (Technology Assessments). The last search was conducted on 24 October 2012. Moreover, systematic reviews and publicly accessible trial registries were searched for further relevant studies, and documents transferred by the G-BA were scrutinized. In addition, organizations were contacted in writing with regard to German-language questionnaires on family history, as were authors of publications of potentially relevant studies in order to clarify essential issues. Depending on the source searched, the selection of relevant studies was performed by 2 reviewers independently of each other or performed by one reviewer and checked by another. After an assessment of study quality the results of the individual studies were presented for the relevant outcomes. Results Sub-goal A: Determination of the risk of disease in people with a positive family history Seven studies could be included in the assessment (2 cohort studies, 5 case-control studies). The overall assessment of the studies included showed that people under 55 years of age with a positive family history for colorectal cancer showed an approximately 1.7- to 4.1-fold higher risk of disease than people of the same age without such a positive family history. The available evidence for people under 55 years of age allowed hardly any further conclusions with regard to different definitions of risk groups. However, the available results indicated that in the group of persons under 55 years of age, the younger the person at risk and the younger the age of the parent at the time of cancer diagnosis, the greater the degree of risk increase. Sub-goal B: Assessment of the diagnostic accuracy of family history tools Overall, the available evidence was very scarce with regard to the diagnostic accuracy of family history tools. No relevant studies could be identified for the age group of interest for the report, i.e. persons under 55 years of age, or for paper-based questionnaires or Germanlanguage tools. Institute for Quality and Efficiency in Health Care (IQWiG) - 2 -

The 2 studies fulfilling the inclusion criteria of the report examined the diagnostic accuracy of family history interviews in persons between 18 and 79 years of age. The calculation of bivariate meta-analyses was not possible, as only 2 studies were available. One study with a low risk of bias reported a sensitivity of 53% (95% CI: [50%; 55%]) with a specificity of 99% (95% CI: [99%; 100%]). The other study showed a high risk of bias and, due to the small sample size, low precision. This study reported a sensitivity of 81% (95% CI: [54%; 95%]) and a specificity of 94% (95% CI: [89%; 96%]). Sub-goal C: Comparative benefit assessment of comprehensive screening strategies using family history tools The systematic search in bibliographic databases and in further sources (systematic reviews, publicly available trial registries and documents transferred by the G-BA) identified no studies for the benefit assessment for sub-goal C. Sub-goal D: Comparative benefit assessment of different screening procedures within a screening strategy in persons with an increased risk due to a positive family history. The systematic search in bibliographic databases and in further sources (systematic reviews, publicly available trial registries, and documents transferred by the G-BA) identified no studies for the benefit assessment for sub-goal D. Three studies were identified that could potentially be considered in a benefit assessment as soon as the study data are published or made publicly accessible. However, it is unclear when the corresponding publications of results will be available and whether they will contain separate analyses for groups of persons under 55 years of age. Conclusion The present assessment found that persons under 55 years with a positive family history for colorectal cancer show an approximately 1.7- to 4.1-fold higher risk of disease than persons of the same age without such a family history. With regard to the diagnostic accuracy of family history tools, no relevant studies could be identified for the age group of interest for the report, i.e. persons under 55 years of age, or for paper-based questionnaires or German-language tools. Interviews for recording family history of colorectal cancer showed a specificity of 94% and 99% and a sensitivity of 81% and 53% in age groups not restricted to under 55-year-olds. No results could be identified from high-quality studies in which comprehensive screening strategies using family history tools in the normal population were evaluated. Likewise, no results could be identified from high-quality studies in which screening procedures within a screening strategy were evaluated in persons with an increased risk due to a positive family history. Due to a lack of suitable studies, the benefit and harm of screening for colorectal cancer is therefore unclear in persons under 55 years of age with a positive family history. Institute for Quality and Efficiency in Health Care (IQWiG) - 3 -

Keywords: colorectal neoplasms, family history, medical history taking, mass screening, systematic review The full report (German version) is published under https://www.iqwig.de/de/projekte_ergebnisse/projekte/nichtmedikamentoese_verfahren/s11_0 1_bewertung_des_nutzens_einer_fruherkennungsuntersuchung_fur_personen_unter_55_jahr en_mit_familiarem_darmkrebsrisiko.1359.html. Institute for Quality and Efficiency in Health Care (IQWiG) - 4 -